Le Hua, MD: Subanalysis of the EXPAND Study of Siponimod in SPMS
March 24th 2020The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed the findings of a subanalysis of the EXPAND study of siponimod in patients with secondary progressive multiple sclerosis.
Le Hua, MD: Considering Age in Multiple Sclerosis Treatment
March 19th 2020The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed the need to take age into consideration when managing a patient with MS, and how the thinking about the disease and age has shifted.
Mary Rensel, MD: Integrating Shared Medical Appointments in MS
March 11th 2020The director of Pediatric MS and Wellness at the Mellen Center and assistant professor of neurology at Cleveland Clinic Lerner College of Medicine describes her study on shared medical appointments and the intricacies of integrating them into the common care realm.
Carrie Hersh, DO, MSc: Measuring Progressive Multiple Sclerosis
March 10th 2020The assistant professor of neurology at the Lerner College of Medicine and neurologist at Luo Ruvo Center for Brain Health, both of Cleveland Clinic, discussed the challenges of current measurements and the need to adjust the reading of progressive MS.
Carrie Hersh, DO, MSc: Addressing Progressive Disease in MS
March 7th 2020The assistant professor of neurology at the Lerner College of Medicine and neurologist at Luo Ruvo Center for Brain Health, both of Cleveland Clinic, spoke to the importance of preventing progression in MS and treating the non-inflammatory aspects of the disease.
Early Administration of Tranexamic Acid May Reduce Intracerebral Hemorrhage in Stroke
February 26th 2020Phase 2 STOP-AUST data suggest that the antifibrinolytic agent may be able to reduce ICH in spot sign positive patients with stroke when administered within 2 to 3 hours of onset, warranting further study.